Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: A cost-effective alternative?

BJU International

Volumn 104, Issue 1, 2009, Pages 41-47

  De Bekker Grob, Esther W ^a   Van Der Aa, Madelon N M ^a   Zwarthoff, Ellen C ^a   Eijkemans, Marinus J C ^a   Van Rhijn, Bas W ^a   Van Der Kwast, Theo H ^a,b   Steyerberg, Ewout W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cost effectiveness; Markov decision model; Microsatellite analysis; Surveillance; Urine test; Urothelial carcinoma

Indexed keywords

AGED; ARTICLE; BLADDER; BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; HEALTH STATUS; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; URINALYSIS;

COST-BENEFIT ANALYSIS; CYSTOSCOPY; EPIDEMIOLOGIC METHODS; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; URINARY BLADDER NEOPLASMS;

EID: 67650500916     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08323.x     Document Type: Article

References (18)

1. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005 66 (6 Suppl. 1 4 34 (Pubitemid 43049607)
2. Almallah YZ, Rennie CD, Stone J, Lancashire MJ. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. Urology 2000 56 : 37 9
3. Denholm SW, Conn IG, Newsam JE, Chisholm GD. Morbidity following cystoscopy: comparison of flexible and rigid techniques. Br J Urol 1990 66 : 152 4
4. Clark KR, Higgs MJ. Urinary infection following out-patient flexible cystoscopy. Br J Urol 1990 66 : 503 5
5. Ross JS, Cohen MB. Ancillary methods for the detection of recurrent urothelial neoplasia. Cancer 2000 90 : 75 86 (Pubitemid 30220096)
6. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003 21 : 1315 30
7. Bartoletti R, Dal Canto M, Cai T et al. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Oncol Rep 2005 13 : 531 7
8. van der Aa MN, Zwarthoff EC, Steyerberg EW et al. Microsatellite analysis of voided-urine samples for surveillence of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). Eur Urol 2008 (in press)
9. Amira N, Mourah S, Rozet F et al. Non-invasive molecular detection of bladder cancer recurrence. Int J Cancer 2002 101 : 293 7
10. Raman JD, Sosa RE, Vaughan ED Jr., Scherr DS. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma. Urology 2007 69 : 251 4
11. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York : Oxford University Press, 1996
12. Grossman HB, Soloway M, Messing E et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006 295 : 299 305 (Pubitemid 43112958)
13. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002 167 : 75 9
14. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004 10 : 1887 93
15. Rieger-Christ KM, Mourtzinos A, Lee PJ et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003 98 : 737 44
16. Miyake M, Sugano K, Kawashima K et al. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. Biochem Biophys Res Commun 2007 362 : 865 71
17. van Oers JM, Lurkin I, van Exsel AJ et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005 11 : 7743 8
18. van Rhijn BW, Lurkin I, Chopin DK et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 2003 9 : 257 63